Are analysts optimistic about Catalent Inc.’s (NYSE:CTLT) stock?

The closing price of Catalent Inc. (NYSE: CTLT) was $49.57 for the day, down -5.74% from the previous closing price of $52.59. In other words, the price has decreased by -$3.02 from its previous closing price. On the day, 2925861 shares were traded. CTLT stock price reached its highest trading level at $53.00 during the session, while it also had its lowest trading level at $49.12.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Ratios:

Our analysis of CTLT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.10 and its Current Ratio is at 2.90. In the meantime, Its Debt-to-Equity ratio is 0.89 whereas as Long-Term Debt/Eq ratio is at 0.87.

Upgrades & Downgrades

BofA Securities Downgraded its Buy to Neutral on November 02, 2022, whereas the target price for the stock was revised from $125 to $60.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 05 when Boerman Manja sold 780 shares for $51.70 per share. The transaction valued at 40,326 led to the insider holds 15,860 shares of the business.

Grippo Michael J sold 2,451 shares of CTLT for $161,349 on Oct 31. The SVP, Strategy & Corp. Dev. now owns 17,792 shares after completing the transaction at $65.83 per share. On Oct 10, another insider, Hawkeswood Thomas W, who serves as the Pres. Pharma Prod Delivery Div of the company, sold 930 shares for $77.46 each. As a result, the insider received 72,038 and left with 5,364 shares of the company.

Valuation Measures:

As of this moment, Catalent’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.20, and their Forward P/E ratio for the next fiscal year is 13.53. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.50. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.84 while its Price-to-Book (P/B) ratio in mrq is 1.90.

Stock Price History:

Over the past 52 weeks, CTLT has reached a high of $115.33, while it has fallen to a 52-week low of $40.69. The 50-Day Moving Average of the stock is 46.23, while the 200-Day Moving Average is calculated to be 82.16.

Shares Statistics:

CTLT traded an average of 3.35M shares per day over the past three months and 2.78M shares per day over the past ten days. A total of 180.00M shares are outstanding, with a floating share count of 179.31M. Shares short for CTLT as of Oct 13, 2022 were 4.3M with a Short Ratio of 5.94M, compared to 3.65M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 2.39% and a Short% of Float of 2.67%.

Earnings Estimates

The firm’s stock currently is rated by 13 analysts. On average, analysts expect EPS of $0.56 for the current quarter, with a high estimate of $0.66 and a low estimate of $0.48, while EPS last year was $0.71. The consensus estimate for the next quarter is $0.8, with high estimates of $0.87 and low estimates of $0.7.

Analysts are recommending an EPS of between $3.9 and $3.62 for the fiscal current year, implying an average EPS of $3.76. EPS for the following year is $4.45, with 15 analysts recommending between $4.83 and $4.19.

Revenue Estimates

A total of 14 analysts have provided revenue estimates for CTLT’s current fiscal year. The highest revenue estimate was $5.18B, while the lowest revenue estimate was $4.98B, resulting in an average revenue estimate of $5.08B. In the same quarter a year ago, actual revenue was $4.83B, up 5.20% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $5.62B in the next fiscal year. The high estimate is $5.81B and the low estimate is $5.51B. The average revenue growth estimate for next year is up 10.60% from the average revenue estimate for this year.